Core Viewpoint - Luoxin Pharmaceutical (002793.SZ) forecasts a net loss of 250 million to 340 million yuan for the year 2025, compared to a loss of 965.4962 million yuan in the previous year [1] Financial Performance - The company anticipates a non-GAAP net loss of 260 million to 350 million yuan for 2025, compared to a loss of 768.1208 million yuan in the same period last year [1] Strategic Focus - In 2025, the company will continue to strategically focus on the pharmaceutical manufacturing sector, particularly in the advantageous digestive system field [1] - The growth of the company's core innovative drug, Tegoprazan (brand name: Taixinzan®), is expected to drive improvements in product structure and growth quality [1]

Group 1 - Shandong Province's Industrial and Information Technology Department has announced the proposed list of the ninth batch of manufacturing single champion enterprises, with two companies from Linyi City successfully selected [1] - Linyi's Luoxin Pharmaceutical Group and Linyi Lixin Aluminum Industry have been recognized, contributing to the region's manufacturing sector's high-end, intelligent, and green development [1] - Luoxin Pharmaceutical, a top 100 pharmaceutical company in China, focuses on digestive system diseases and has developed innovative drugs, including the national Class I innovative drug Tegoprazan, which is included in the 2025 National Medical Insurance Directory [1] Group 2 - Linyi Lixin Aluminum Industry is transforming the aluminum industry with a "short-process green industrial chain," achieving over 90% recycling rate of aluminum resources through its innovative model [2] - The company plans to expand its production capacity to 300,000 tons per year by 2026, with an expected annual sales revenue of 2.5 billion yuan [2] - Lixin Aluminum holds 14 national invention patents and 42 utility model patents, and has established five provincial and municipal R&D platforms, collaborating with universities to achieve internationally advanced technology levels [2] Group 3 - The Linyi district will enhance the cultivation mechanism for manufacturing single champion enterprises by providing targeted policy guidance and financial support [2] - The district aims to encourage technological breakthroughs and promote the transformation of scientific achievements [2] - A collaborative industrial community will be built, integrating leading enterprises with small and medium-sized suppliers [2]